SCHEMBL4491933

SCHEMBL4491933

O=C(O)C1CCCN(C(=O)c2cnccn2)C1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.58
MAPT P10636 2/20 0.48
GAA P10253 1/20 0.46
CYP3A4 P08684 8/20 0.46
ALDH1A1 P00352 5/20 0.46
USP2 O75604 4/20 0.46
CYP1A2 P05177 2/20 0.46
HIF1A Q16665 2/20 0.45
PLA2G1B P04054 1/20 0.45
ATG4B Q9Y4P1 1/20 0.45
HSD17B10 Q99714 2/20 0.44
MEN1 O00255 1/20 0.44
POLB P06746 1/20 0.44
PKM P14618 1/20 0.44
BLM P54132 1/20 0.44
KMT2A Q03164 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
HPGD P15428 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4491936 1.00 KDM4E (0.58) KDM4EMAPTGAACYP3A4ALDH1A1
SCHEMBL4491941 1.00 KDM4E (0.58) KDM4EMAPTGAACYP3A4ALDH1A1
SCHEMBL4511009 0.83 CYP3A4 (0.52) KDM4EGAACYP3A4ALDH1A1USP2
SCHEMBL12531236 0.82 KDM4E (0.51) KDM4EGAACYP3A4ALDH1A1USP2
SCHEMBL13198908 0.82 RECQL (0.62) KDM4EGAACYP3A4ALDH1A1USP2
SCHEMBL4485391 0.81 PLA2G1B (0.65) CYP3A4ALDH1A1PLA2G1BATG4BMEN1
SCHEMBL4485387 0.81 PLA2G1B (0.65) CYP3A4ALDH1A1PLA2G1BATG4BMEN1
SCHEMBL12442612 0.81 CYP3A4 (0.58) GAACYP3A4ALDH1A1USP2CYP1A2
SCHEMBL31087166 0.81 CYP3A4 (0.58) GAACYP3A4ALDH1A1USP2CYP1A2
SCHEMBL4494471 0.80 PLA2G1B (0.47) KDM4EMAPTALDH1A1PLA2G1BATG4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7598392-B2 2-amido-4-phenylthiazole derivatives, the preparation and the therapeutic use thereof SANOFI-AVENTIS (FR) 2009-10-06 US claimed
US-20070259847-A1 2-Amido-4-phenylthiazole Derivatives, The Preparation And The Therapeutic Use Thereof SANOFI-AVENTIS (FR) 2007-11-08 US claimed
US-7598392-B2 2-amido-4-phenylthiazole derivatives, the preparation and the therapeutic use thereof SANOFI-AVENTIS (FR) 2009-10-06 US disclosed
US-20070259847-A1 2-Amido-4-phenylthiazole Derivatives, The Preparation And The Therapeutic Use Thereof SANOFI-AVENTIS (FR) 2007-11-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259847-A1 2-Amido-4-phenylthiazole Derivatives, The Preparation And The Therapeutic Use Thereof PKD2, TPMT, PKD1 KDM4E 1646/4885MAPT 30/4885GAA 694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.